Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobitolimod in moderate to severe active ulcerative colitis
NCT03178669Phase 2Completed
- Sponsor
- InDex Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Aug 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 10
01
Overview
A Phase 2 trial of cobitolimod in ulcerative colitis (UC), sponsored by InDex Pharmaceuticals. Started Jun 2017; status: completed.
02
Drugs
cobitolimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03178669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178669.